Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03935074

Enrollment

Registered

2019-05-02

Start date

2016-08-30

Completion date

2016-11-30

Last updated

2019-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinoblastoma

Keywords

enucleation, globe salvage, superselective intra-arterial chemotherapy

Brief summary

Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute. The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.

Interventions

DRUGintra-arterial administration of melphalan

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

5 Months to 7 Years

Inclusion criteria

* patients diagnosed with unilateral/bilateral retinoblastoma

Exclusion criteria

* patients with trilateral retinoblastoma * extraoculer involvement * patients with blood dyscrasias, bleeding and clotting disorders

Design outcomes

Primary

Measure	Time frame	Description
globe salvage	2-5 years	globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026